Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
BörsenkürzelBBLG
Name des UnternehmensBone Biologics Corp
IPO-datumNov 27, 2015
Gegründet am2007
CEOMr. Jeffrey Frelick
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeNov 27
Addresse2 Burlington Woods Dr Ste 100
StadtBURLINGTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl01803-4551
Telefon17815524452
Websitehttps://www.bonebiologics.com/
BörsenkürzelBBLG
IPO-datumNov 27, 2015
Gegründet am2007
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten